Pharvaris (NASDAQ:PHVS) Insider Sells $112,213.98 in Stock

Key Points

• Insider Peng Lu sold a total of 25,834 shares of Pharvaris in multiple April transactions for approximately $779,200, materially reducing his stake in the company.
• Pharvaris shares fell about 5.1% to $29.44 on heavy trading (512,191 shares vs. a ~245,049 average), reflecting notable market reaction to the insider activity and other news.
• The company recently missed quarterly EPS estimates (reported -$0.84 vs. -$0.69 expected) while analysts maintain a consensus rating of "Moderate Buy" with an average price target of $42.73.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Peng Lu sold 3,733 shares of Pharvaris stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $30.06, for a total value of $112,213.98. Following the completion of the sale, the insider directly owned 62,350 shares in the company, valued at approximately $1,874,241. This represents a 5.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Peng Lu also recently made the following trade(s):

• On Thursday, April 30th, Peng Lu sold 15,000 shares of Pharvaris stock. The shares were sold at an average price of $30.24, for a total value of $453,600.00.
• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,380.05.

Pharvaris Stock Down 5.1%

Pharvaris stock traded down $1.57 during midday trading on Friday, reaching $29.44. The stock had a trading volume of 512,191 shares, compared to its average volume of 245,049. The firm's fifty day simple moving average is $27.62 and its 200-day simple moving average is $26.03. Pharvaris N.V. has a 1-year low of $14.59 and a 1-year high of $31.14.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.15). On average, analysts predict that Pharvaris N.V. will post -3.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PHVS. Wellington Management Group LLP bought a new position in shares of Pharvaris during the 3rd quarter worth approximately $43,282,000. Paradigm Biocapital Advisors LP boosted its stake in shares of Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company's stock worth $45,796,000 after acquiring an additional 772,583 shares during the period. Balyasny Asset Management L.P. bought a new position in shares of Pharvaris during the 3rd quarter worth approximately $15,613,000. Commodore Capital LP boosted its stake in shares of Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company's stock worth $60,341,000 after acquiring an additional 507,043 shares during the period. Finally, General Atlantic L.P. boosted its stake in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company's stock worth $200,380,000 after acquiring an additional 500,000 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on PHVS shares. Royal Bank Of Canada lowered their price target on Pharvaris from $52.00 to $51.00 and set an "outperform" rating on the stock in a research report on Monday, April 6th. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of Pharvaris in a research report on Tuesday, March 3rd. Wedbush boosted their price target on Pharvaris from $41.00 to $42.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 7th. Wall Street Zen lowered Pharvaris from a "sell" rating to a "strong sell" rating in a research report on Monday, April 13th. Finally, Wolfe Research started coverage on Pharvaris in a research report on Thursday, April 9th. They set an "outperform" rating and a $42.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Pharvaris currently has a consensus rating of "Moderate Buy" and an average price target of $42.73.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.